Drug Patents Expiring in 2031
1. Abilify Mycite Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11229378 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jul, 2031
(6 years from now) | |
| US9320455 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
ABILIFY MYCITE KIT family patents
2. Accrufer patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248148 | SHIELD TX | Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2024 |
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: 26 July, 2023
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating iron deficiency
Dosage: CAPSULE
More Information on Dosage
ACCRUFER family patents
3. Acetadote patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9327028 | CUMBERLAND PHARMS | Acetylcysteine compositions and methods of use thereof |
Jul, 2031
(6 years from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Market Authorisation Date: 23 January, 2004
Treatment: Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy
Dosage: INJECTABLE
How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage
ACETADOTE family patents
4. Adlyxin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8882721 | SANOFI-AVENTIS US | Drive assembly suitable for use in a drug delivery device and drug delivery device |
Jun, 2031
(6 years from now) | |
| US9084853 | SANOFI-AVENTIS US | Drive mechanism for a drug delivery device and drug delivery device |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ADLYXIN family patents
5. Afrezza patent expiration
AFREZZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358352 | MANNKIND | Dry powder drug delivery system and methods |
Feb, 2031
(6 years from now) | |
| US8227409 | MANNKIND | Diketopiperazine microparticles with defined isomer contents |
Mar, 2031
(6 years from now) | |
| US9597374 | MANNKIND | Use of ultrarapid acting insulin |
Oct, 2031
(6 years from now) | |
| US8424518 | MANNKIND | Dry powder inhaler and system for drug delivery |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2017 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 27 June, 2014
Treatment: Use of an inhaler to administer dry powder medicament; Administration of fdkp microparticles comprising insulin.; Method of controlling glycemia in diabetics by administering an initial dose of insuli...
Dosage: POWDER
More Information on Dosage
AFREZZA family patents
6. Airduo Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10195375 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2031
(6 years from now) | |
| US10022510 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US9731087 | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | |
| US10124131 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US9216260 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(6 years from now) | |
|
US10195375 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2031
(6 years from now) | |
|
US10022510 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Nov, 2031
(6 years from now) | |
|
US10124131 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Nov, 2031
(6 years from now) | |
|
US9731087 (Pediatric) | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
Nov, 2031
(6 years from now) | |
|
US9216260 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO DIGIHALER family patents
7. Airduo Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10195375 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2031
(6 years from now) | |
| US10022510 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US9731087 | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | |
| US10124131 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US9216260 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(6 years from now) | |
|
US10195375 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2031
(6 years from now) | |
|
US9731087 (Pediatric) | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
Nov, 2031
(6 years from now) | |
|
US10022510 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Nov, 2031
(6 years from now) | |
|
US10124131 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Nov, 2031
(6 years from now) | |
|
US9216260 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO RESPICLICK family patents
8. Akeega patent expiration
AKEEGA's oppositions filed in EPO
AKEEGA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8071623 | JANSSEN BIOTECH | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859562 | JANSSEN BIOTECH | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET
More Information on Dosage
AKEEGA family patents
9. Aklief patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807708 | GALDERMA LABS LP | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 04, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 05 October, 2023
Market Authorisation Date: 04 October, 2019
Treatment: NA
Dosage: CREAM
More Information on Dosage
AKLIEF family patents
10. Akynzeo patent expiration
AKYNZEO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9271975 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 19, 2023 |
Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 10 October, 2014
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limite...
Dosage: CAPSULE
More Information on Dosage
AKYNZEO family patents
11. Alecensa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9126931 | HOFFMANN-LA ROCHE | Tetracyclic compound |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-756) | Nov 06, 2020 |
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2020 |
| Orphan Drug Exclusivity(ODE-105) | Dec 11, 2022 |
| Orphan Drug Exclusivity(ODE) | Nov 06, 2024 |
| Orphan Drug Exclusivity(ODE-159) | Nov 06, 2024 |
| New Indication(I-947) | Apr 18, 2027 |
| Orphan Drug Exclusivity(ODE-477) | Apr 18, 2031 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2019
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage
ALECENSA family patents
12. Alunbrig patent expiration
ALUNBRIG's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9012462 | TAKEDA PHARMS USA | Phosphorous derivatives as kinase inhibitors |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| New Indication(I-847) | May 22, 2023 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-142) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-300) | May 22, 2027 |
Drugs and Companies using BRIGATINIB ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
ALUNBRIG family patents
13. Angeliq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8906890 | BAYER HLTHCARE | Very low-dosed solid oral dosage forms for HRT |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Mar 01, 2015 |
Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient
Market Authorisation Date: 29 February, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of ANGELIQ before it's drug patent expiration?
More Information on Dosage
ANGELIQ family patents
14. Anoro Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: NA
Dosage: POWDER
More Information on Dosage
ANORO ELLIPTA family patents
15. Apadaz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8461137 | ZEVRA THERAP | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
Feb, 2031
(6 years from now) | |
Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 January, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
APADAZ family patents
16. Apretude patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 20 December, 2021
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
APRETUDE family patents
17. Armonair Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10195375 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2031
(6 years from now) | |
|
US8714149 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
May, 2031
(6 years from now) | |
| US10124131 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US10022510 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US9731087 | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | |
| US9216260 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(6 years from now) | |
|
US10195375 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2031
(6 years from now) | |
|
US10124131 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Nov, 2031
(6 years from now) | |
|
US9731087 (Pediatric) | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
Nov, 2031
(6 years from now) | |
|
US10022510 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Nov, 2031
(6 years from now) | |
|
US9216260 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR DIGIHALER family patents
18. Armonair Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10195375 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2031
(6 years from now) | |
| US9731087 | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | |
| US10124131 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US10022510 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US9216260 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(6 years from now) | |
|
US10195375 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2031
(6 years from now) | |
|
US10022510 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Nov, 2031
(6 years from now) | |
|
US9731087 (Pediatric) | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
Nov, 2031
(6 years from now) | |
|
US10124131 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Nov, 2031
(6 years from now) | |
|
US9216260 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR RESPICLICK family patents
19. Arnuity Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 20, 2017 |
| New Patient Population(NPP) | May 17, 2021 |
| New Strength(NS) | May 17, 2021 |
| M(M-290) | Mar 01, 2026 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARNUITY ELLIPTA family patents
20. Aubagio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8802735 (Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage
AUBAGIO family patents
21. Austedo patent expiration
AUSTEDO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733 (Pediatric) | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-751) | Aug 30, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
| Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
| M(M-54) | Jun 24, 2024 |
| Pediatric Exclusivity(PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage
AUSTEDO family patents
22. Austedo Xr patent expiration
AUSTEDO XR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733 (Pediatric) | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(6 years from now) | |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
AUSTEDO XR family patents
23. Avycaz patent expiration
AVYCAZ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8471025 | ABBVIE | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-738) | Jun 22, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2020 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 25, 2025 |
| New Patient Population(NPP) | Dec 20, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 26 February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: POWDER
More Information on Dosage
AVYCAZ family patents
24. Balversa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9464071 | JANSSEN BIOTECH | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
| New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic the...
Dosage: TABLET
How can I launch a generic of BALVERSA before it's drug patent expiration?
More Information on Dosage
BALVERSA family patents
25. Barhemsys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10525033 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(6 years from now) | |
| US9545426 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(6 years from now) | |
| US9889118 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 27 February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: Prevention of post-operative nausea and vomiting
Dosage: SOLUTION
More Information on Dosage
BARHEMSYS family patents
26. Baxdela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| New Indication(I-815) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: NA
Dosage: TABLET; POWDER
More Information on Dosage
BAXDELA family patents
27. Belrapzo patent expiration
BELRAPZO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11872214 | EAGLE PHARMS | Formulations of Bendamustine |
Jan, 2031
(6 years from now) | |
| US9572797 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US11103483 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US11844783 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US9572796 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US10010533 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US9265831 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US8609707 | EAGLE PHARMS | Formulations of bendamustine |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 May, 2018
Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma
Dosage: SOLUTION
How can I launch a generic of BELRAPZO before it's drug patent expiration?
More Information on Dosage
BELRAPZO family patents
28. Belviq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9770455 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 27 June, 2012
Treatment: Method for chronic weight management in patients with moderate renal impairment who are obese, or overweight and have at least one weight related comorbid condition
Dosage: TABLET
How can I launch a generic of BELVIQ before it's drug patent expiration?
More Information on Dosage
BELVIQ family patents
29. Belviq Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10226471 | EISAI INC | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
Aug, 2031
(6 years from now) | |
| US9770455 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Aug, 2031
(6 years from now) | |
| US10463676 | EISAI INC | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 15 July, 2016
Treatment: Method for chronic weight management in patients with moderate renal impairment who are obese, or overweight and have at least one weight related comorbid condition; Chronic weight management in adult...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage
BELVIQ XR family patents
30. Bendeka patent expiration
BENDEKA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10010533 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US9265831 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US11103483 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US9572796 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US11844783 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US11872214 | EAGLE PHARMS | Formulations of Bendamustine |
Jan, 2031
(6 years from now) | |
| US9572797 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US8609707 | EAGLE PHARMS | Formulations of bendamustine |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-179) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For use in the treatment of patients with chronic lymphocytic ...
Dosage: SOLUTION
How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage
BENDEKA family patents
31. Besivance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8481526 | BAUSCH AND LOMB | Fluoroquinolone carboxylic acid molecular crystals |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2014 |
Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient
NCE-1 date: 28 May, 2013
Market Authorisation Date: 28 May, 2009
Treatment: NA
Dosage: SUSPENSION/DROPS
More Information on Dosage
BESIVANCE family patents
32. Bevespi Aerosphere patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815258 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 25, 2019 |
Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED
More Information on Dosage
BEVESPI AEROSPHERE family patents
33. Bevyxxa patent expiration
BEVYXXA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8404724 | PORTOLA PHARMS INC | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 23 June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: Inhibiting coagulation
Dosage: CAPSULE
More Information on Dosage
BEVYXXA family patents
34. Binosto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9592195 | RADIUS | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
Dec, 2031
(6 years from now) | |
Drugs and Companies using ALENDRONATE SODIUM ingredient
Market Authorisation Date: 12 March, 2012
Treatment: NA
Dosage: TABLET, EFFERVESCENT
More Information on Dosage
BINOSTO family patents
35. Braftovi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501758 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Mar, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-826) | Apr 08, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
| Orphan Drug Exclusivity(ODE-445) | Oct 11, 2030 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with metastatic non small cell lung cancer with a braf v600e mutation, as detected by an fda-app...
Dosage: CAPSULE
How can I launch a generic of BRAFTOVI before it's drug patent expiration?
More Information on Dosage
BRAFTOVI family patents
36. Brenzavvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10981942 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jun, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533032 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 20 January, 2027
Market Authorisation Date: 20 January, 2023
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET
More Information on Dosage
BRENZAVVY family patents
37. Breo Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8746242 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 30, 2018 |
| New Indication(I-708) | Apr 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
| M(M-202) | May 15, 2020 |
| New Patient Population(NPP) | May 13, 2026 |
| New Strength(NS) | May 13, 2026 |
| Pediatric Exclusivity(PED) | Nov 13, 2026 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: NA
Dosage: POWDER
More Information on Dosage
BREO ELLIPTA family patents
38. Breztri Aerosphere patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815258 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2023 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 23 July, 2020
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED
More Information on Dosage
BREZTRI AEROSPHERE family patents
39. Bryhali patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12076403 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| US11957753 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| US11986527 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| US11839656 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 06, 2021 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 06 November, 2018
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION
How can I launch a generic of BRYHALI before it's drug patent expiration?
More Information on Dosage
BRYHALI family patents
40. Bydureon Bcise patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8895033 (Pediatric) | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2020 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON BCISE family patents
41. Byfavo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10342800 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(6 years from now) | |
| US9737547 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(6 years from now) | |
| US10722522 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(6 years from now) | |
| US10052334 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(6 years from now) | |
| US10195210 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: 06 October, 2024
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER
More Information on Dosage
BYFAVO family patents
42. Bylvay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10093697 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(6 years from now) | |
| US10011633 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(6 years from now) | |
| US10487111 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(6 years from now) | |
| US9694018 | IPSEN | IBAT inhibitors for the treatment of liver disease |
Nov, 2031
(6 years from now) | |
| US11732006 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(6 years from now) | |
| US10981952 | IPSEN | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-918) | Jun 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity(ODE-363) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-436) | Jun 13, 2030 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: 20 July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of reducing serum bile acids in patients 12 months or older suffering from alagille syndrome (algs); Method of treating cholestatic pruritus in patients 12 months or older suffering from alagil...
Dosage: CAPSULE; CAPSULE, PELLETS
More Information on Dosage
BYLVAY family patents
43. Cabenuva Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11224597 | VIIV HLTHCARE | Pharmaceutical compositions |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-184) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
CABENUVA KIT family patents
44. Cabometyx patent expiration
CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039757 | EXELIXIS INC | C-Met modulator pharmaceutical compositions |
Jul, 2031
(6 years from now) | |
| US10034873 | EXELIXIS INC | C-met modulator pharmaceutical compositions |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-760) | Dec 19, 2020 |
| New Indication(I-792) | Jan 14, 2022 |
| New Indication(I-854) | Jan 22, 2024 |
| New Indication(I-873) | Sep 17, 2024 |
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of advanced renal cell carcinoma; Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib
Dosage: TABLET
How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage
CABOMETYX family patents
45. Cerdelga patent expiration
CERDELGA's oppositions filed in EPO
CERDELGA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888547 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2019 |
| Orphan Drug Exclusivity(ODE) | Aug 19, 2021 |
| Orphan Drug Exclusivity(ODE-73) | Aug 19, 2021 |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
NCE-1 date: 19 August, 2018
Market Authorisation Date: 19 August, 2014
Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twic...
Dosage: CAPSULE
How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage
CERDELGA family patents
46. Cleviprex patent expiration
CLEVIPREX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103490 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(6 years from now) | |
| US8658676 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(6 years from now) | |
| US10010537 | CHIESI | Clevidipine emulsion formulations containing antimicrobial agents |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2013 |
Drugs and Companies using CLEVIDIPINE ingredient
NCE-1 date: 01 August, 2012
Market Authorisation Date: 01 August, 2008
Treatment: NA
Dosage: EMULSION
How can I launch a generic of CLEVIPREX before it's drug patent expiration?
More Information on Dosage
CLEVIPREX family patents
47. Combogesic Iv patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11896567 | HIKMA | Combination composition |
Oct, 2031
(6 years from now) | |
| US11446266 | HIKMA | Combination composition |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using ACETAMINOPHEN; IBUPROFEN SODIUM ingredient
Market Authorisation Date: 17 October, 2023
Treatment: Method of treating moderate to severe pain in adults as an adjunct to opioid analgesics
Dosage: SOLUTION
More Information on Dosage
COMBOGESIC IV family patents
48. Contrave patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033543 | NALPROPION | Methods of providing weight loss therapy in patients with major depression |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage
CONTRAVE family patents
49. Cosela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8598186 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(6 years from now) | |
| US8598197 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(6 years from now) | |
| US9957276 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(6 years from now) | |
| US10189849 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10189850 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(6 years from now) | |
| US11040042 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Oct, 2031
(6 years from now) | |
| US10927120 | PHARMACOSMOS | CDK inhibitors |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 12 February, 2025
Market Authorisation Date: 12 February, 2021
Treatment: NA
Dosage: POWDER
More Information on Dosage
COSELA family patents
50. Daklinza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8629171 | BRISTOL-MYERS SQUIBB | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-161) | Feb 05, 2019 |
| New Dosing Schedule(D-162) | Feb 05, 2019 |
| New Indication(I-726) | Feb 05, 2019 |
| New Indication(I-727) | Feb 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2020 |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
NCE-1 date: 25 July, 2019
Market Authorisation Date: 24 July, 2015
Treatment: Method of inhibiting hepatitis c virus
Dosage: TABLET
More Information on Dosage
DAKLINZA family patents
51. Daurismo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148401 | PFIZER | Benzimidazole derivatives |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 21, 2023 |
| Orphan Drug Exclusivity(ODE-224) | Nov 21, 2025 |
Drugs and Companies using GLASDEGIB MALEATE ingredient
NCE-1 date: 21 November, 2022
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
DAURISMO family patents
52. Dayvigo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8268848 | EISAI INC | Cyclopropane compound |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2025 |
| M(M-293) | Apr 20, 2026 |
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: 07 April, 2024
Market Authorisation Date: 07 April, 2020
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
Dosage: TABLET
More Information on Dosage
DAYVIGO family patents
53. Delstrigo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486975 | MSD MERCK CO | Non-nucleoside reverse transcriptase inhibitors |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-806) | Sep 19, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2023 |
| New Patient Population(NPP) | Jan 27, 2025 |
Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
NCE-1 date: 30 August, 2022
Market Authorisation Date: 30 August, 2018
Treatment: Treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically...
Dosage: TABLET
How can I launch a generic of DELSTRIGO before it's drug patent expiration?
More Information on Dosage
DELSTRIGO family patents
54. Docetaxel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10842770 | SHILPA | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
Aug, 2031
(6 years from now) | |
Drugs and Companies using DOCETAXEL ingredient
Market Authorisation Date: 22 December, 2015
Treatment: Method of administering docetaxel to a subject combining the docetaxel pro-emulsion formulation with an aqueous medium to produce docetaxel emulsion
Dosage: INJECTABLE
More Information on Dosage
DOCETAXEL family patents
55. Dovato patent expiration
DOVATO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11234985 | VIIV HLTHCARE | Antiviral therapy |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 08, 2022 |
| New Indication(I-839) | Aug 06, 2023 |
| New Patient Population(NPP) | Apr 05, 2027 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 08 April, 2019
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage
DOVATO family patents
56. Drospirenone patent expiration
DROSPIRENONE's oppositions filed in EPO
Can you believe DROSPIRENONE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11123299 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11439598 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11351122 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US10603281 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | |
| US10849857 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | |
| US11478487 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11951213 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US12090231 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11413249 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US9603860 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | |
| US10179140 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | |
| US11504334 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11291633 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US10987364 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11291632 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 29, 2025 |
Drugs and Companies using DROSPIRENONE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Prevention of pregnancy in females of reproductive age
Dosage: TABLET, CHEWABLE
More Information on Dosage
DROSPIRENONE family patents
57. Dsuvia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8945592 | VERTICAL PHARMS | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 02, 2021 |
Drugs and Companies using SUFENTANIL CITRATE ingredient
Market Authorisation Date: 02 November, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
DSUVIA family patents
58. Duobrii patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11986527 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| US10478502 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| US8809307 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| US12076403 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| US11839656 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| US11957753 | BAUSCH | Pharmaceutical formulations containing corticosteroids for topical administration |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 25, 2022 |
Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient
Market Authorisation Date: 25 April, 2019
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION
How can I launch a generic of DUOBRII before it's drug patent expiration?
More Information on Dosage
DUOBRII family patents
59. Durysta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8629185 | ABBVIE | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: NA
Dosage: IMPLANT
More Information on Dosage
DURYSTA family patents
60. Duzallo patent expiration
DUZALLO's oppositions filed in EPO
Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216179 | IRONWOOD PHARMS INC | Treatment of gout and hyperuricemia |
Aug, 2031
(6 years from now) | |
| US9956205 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Dec, 2031
(7 years from now) | |
Drugs and Companies using ALLOPURINOL; LESINURAD ingredient
Market Authorisation Date: 18 August, 2017
Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone
Dosage: TABLET
More Information on Dosage
DUZALLO family patents
61. Ecoza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10071054 | RESILIA PHARMS | Econazole composition and methods of treatment therewith |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 24, 2016 |
Drugs and Companies using ECONAZOLE NITRATE ingredient
Market Authorisation Date: 24 October, 2013
Treatment: NA
Dosage: AEROSOL, FOAM
More Information on Dosage
ECOZA family patents
62. Edarbyclor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9387249 | AZURITY | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Dec 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 20 December, 2011
Treatment: Treatment of hypertension
Dosage: TABLET
How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage
EDARBYCLOR family patents
63. Edluar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265720 | MYLAN SPECIALITY LP | Pharmaceutical formulations useful in the treatment of insomnia |
Feb, 2031
(6 years from now) | |
Drugs and Companies using ZOLPIDEM TARTRATE ingredient
Market Authorisation Date: 13 March, 2009
Treatment: Method of treating insomnia characterized by difficulty with sleep onset
Dosage: TABLET
How can I launch a generic of EDLUAR before it's drug patent expiration?
More Information on Dosage
EDLUAR family patents
64. Eliquis patent expiration
ELIQUIS's oppositions filed in EPO
ELIQUIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9326945 | BRISTOL MYERS SQUIBB | Apixaban formulations |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-681) | Mar 03, 2017 |
| New Indication(I-661) | Aug 21, 2017 |
| New Indication(I-690) | Aug 21, 2017 |
| New Indication(I-691) | Aug 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Dec 28, 2017 |
Drugs and Companies using APIXABAN ingredient
NCE-1 date: 28 December, 2016
Market Authorisation Date: 28 December, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of ELIQUIS before it's drug patent expiration?
More Information on Dosage
ELIQUIS family patents
65. Enstilar patent expiration
ENSTILAR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10682364 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(6 years from now) | |
| US9566286 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(6 years from now) | |
| US10617698 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(6 years from now) | |
| US10688108 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(6 years from now) | |
| US10716799 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(6 years from now) | |
| US10130640 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(6 years from now) | |
| US10660908 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(6 years from now) | |
| US9119781 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(6 years from now) | |
|
US9119781 (Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(6 years from now) | |
|
US10130640 (Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 16, 2018 |
| New Patient Population(NPP) | Jul 30, 2022 |
| Pediatric Exclusivity(PED) | Jan 30, 2023 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient
Market Authorisation Date: 16 October, 2015
Treatment: Topical treatment of plaque psoriasis in patients 12 years and older
Dosage: AEROSOL, FOAM
How can I launch a generic of ENSTILAR before it's drug patent expiration?
More Information on Dosage
ENSTILAR family patents
66. Epclusa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| New Patient Population(NPP) | Mar 19, 2023 |
| New Strength(NS) | Mar 19, 2023 |
| M(M-264) | Jul 14, 2023 |
| M(M-277) | Apr 27, 2025 |
| Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 10 June, 2021
Treatment: NA
Dosage: PELLETS; TABLET
More Information on Dosage
EPCLUSA family patents
67. Evzio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US10143972 | KALEO INC | Ultrafiltration membrane and a preparation method thereof |
May, 2031
(6 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone
Dosage: SOLUTION
More Information on Dosage
EVZIO family patents
68. Evzio (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US10143792 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
May, 2031
(6 years from now) | |
| US10143972 | KALEO INC | Ultrafiltration membrane and a preparation method thereof |
May, 2031
(6 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone
Dosage: SOLUTION
More Information on Dosage
EVZIO (AUTOINJECTOR) family patents
69. Fanapt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9072742 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(6 years from now) | |
| US9074256 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(6 years from now) | |
| US9074254 | VANDA PHARMS INC | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2014 |
| M(M-180) | May 26, 2019 |
| New Indication(I-939) | Apr 02, 2027 |
Drugs and Companies using ILOPERIDONE ingredient
NCE-1 date: 06 May, 2013
Market Authorisation Date: 06 May, 2009
Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone
Dosage: TABLET
How can I launch a generic of FANAPT before it's drug patent expiration?
More Information on Dosage
FANAPT family patents
70. Fetzima patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8481598 | ABBVIE | Stable dosage forms of levomilnacipran |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE*(NCE*) | Jul 25, 2018 |
| M(M-249) | Oct 07, 2022 |
| M(M-304) | Mar 24, 2026 |
Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Treatment of major depressive disorder (mdd)
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of FETZIMA before it's drug patent expiration?
More Information on Dosage
FETZIMA family patents
71. Flyrcado patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9603951 | GE HLTHCARE | Methods and apparatus for synthesizing imaging agents, and intermediates thereof |
May, 2031
(6 years from now) | |
| US8936777 | GE HLTHCARE | Methods and apparatus for synthesizing imaging agents, and intermediates thereof |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2029 |
Drugs and Companies using FLURPIRIDAZ F-18 ingredient
NCE-1 date: 27 September, 2028
Market Authorisation Date: 27 September, 2024
Treatment: Method of positron emission tomography (pet) for cardiac imaging
Dosage: SOLUTION
More Information on Dosage
FLYRCADO family patents
72. Galafold patent expiration
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48608 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE
How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage
GALAFOLD family patents
73. Gelnique patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8920392 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 27, 2012 |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin
Dosage: GEL
How can I launch a generic of GELNIQUE before it's drug patent expiration?
More Information on Dosage
GELNIQUE family patents
74. Giapreza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9572856 | LA JOLLA PHARMA | Method of treating low blood pressure |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: 21 December, 2021
Market Authorisation Date: 23 December, 2021
Treatment: Treating refractory hypotension with about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor
Dosage: SOLUTION
How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage
GIAPREZA family patents
75. Giazo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8497256 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 03, 2015 |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 03 February, 2012
Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients
Dosage: TABLET
How can I launch a generic of GIAZO before it's drug patent expiration?
More Information on Dosage
GIAZO family patents
76. Gilotrif patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10004743 (Pediatric) | BOEHRINGER INGELHEIM | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 12, 2018 |
| New Indication(I-730) | Apr 15, 2019 |
| Orphan Drug Exclusivity(ODE-50) | Jul 12, 2020 |
| New Indication(I-763) | Jan 12, 2021 |
| Orphan Drug Exclusivity(ODE) | Apr 15, 2023 |
| Orphan Drug Exclusivity(ODE-115) | Apr 15, 2023 |
| Orphan Drug Exclusivity(ODE-230) | Jan 12, 2025 |
| M(M-276) | Apr 07, 2025 |
| Pediatric Exclusivity(PED) | Oct 07, 2025 |
Drugs and Companies using AFATINIB DIMALEATE ingredient
NCE-1 date: 07 October, 2024
Market Authorisation Date: 12 July, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of GILOTRIF before it's drug patent expiration?
More Information on Dosage
GILOTRIF family patents
77. Harvoni patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-153) | Nov 12, 2018 |
| New Indication(I-718) | Nov 12, 2018 |
| New Indication(I-719) | Nov 12, 2018 |
| New Indication(I-720) | Nov 12, 2018 |
| New Dosing Schedule(D-158) | Feb 12, 2019 |
| New Dosing Schedule(D-159) | Feb 12, 2019 |
| New Dosing Schedule(D-160) | Feb 12, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Apr 07, 2020 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-136) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Treatment: NA
Dosage: PELLETS; TABLET
More Information on Dosage
HARVONI family patents
78. Hysingla Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9572779 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US8808740 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US9872837 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US9750703 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
| US9861584 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(7 years from now) | |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 20 November, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of HYSINGLA ER before it's drug patent expiration?
More Information on Dosage
HYSINGLA ER family patents
79. Imbruvica patent expiration
IMBRUVICA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478439 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US9814721 | PHARMACYCLICS LLC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(6 years from now) | |
| US10653696 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(6 years from now) | |
| US9801883 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US9125889 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US10016435 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US8754090 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US9801881 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(6 years from now) | |
| US10004746 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US8999999 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US11672803 | PHARMACYCLICS LLC | Use of inhibitors of Brutons tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
| US10751342 | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(6 years from now) | |
|
US9814721 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Dec, 2031
(6 years from now) | |
|
US8754090 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(6 years from now) | |
|
US9125889 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(6 years from now) | |
|
US10004746 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(6 years from now) | |
|
US9801883 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(6 years from now) | |
|
US9801881 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(6 years from now) | |
|
US8999999 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(6 years from now) | |
|
US10016435 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(6 years from now) | |
|
US10751342 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(6 years from now) | |
|
US10478439 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(6 years from now) | |
|
US10653696 (Pediatric) | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of chronic lymphocytic leukemia; Treatment of marginal zone lymphoma; Treatment of mantle cell lymphoma; Treatment of adult patients with small lymphocytic lymphoma (sll) with 17p deletion; ...
Dosage: TABLET; CAPSULE; SUSPENSION
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
80. Ingrezza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8039627 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
| New Indication(I-925) | Aug 18, 2026 |
| Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage
INGREZZA family patents
81. Ingrezza Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8039627 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-925) | Aug 18, 2026 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
Market Authorisation Date: 30 April, 2024
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
INGREZZA SPRINKLE family patents
82. Inlyta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8791140 (Pediatric) | PF PRISM CV | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage
INLYTA family patents
83. Inomax patent expiration
INOMAX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9295802 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US9408993 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US8573210 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US8291904 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US8776795 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US8776794 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US8573209 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US9265911 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
|
US8776795 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(6 years from now) | |
|
US8776794 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(6 years from now) | |
|
US8573210 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(6 years from now) | |
|
US9265911 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(6 years from now) | |
|
US9295802 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(6 years from now) | |
|
US8573209 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(6 years from now) | |
|
US8291904 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(6 years from now) | |
|
US9408993 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-132) | Dec 21, 2013 |
| Pediatric Exclusivity(PED) | Jun 21, 2014 |
| M(M-167) | Oct 09, 2018 |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: A method of providing a predetermined concentration of nitric oxide to a patient; A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery...
Dosage: GAS
How can I launch a generic of INOMAX before it's drug patent expiration?
More Information on Dosage
INOMAX family patents
84. Inrebic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7528143 | BRISTOL-MYERS | Bi-aryl meta-pyrimidine inhibitors of kinases |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| Orphan Drug Exclusivity(ODE-259) | Aug 16, 2026 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
INREBIC family patents
85. Intrarosa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268806 | MILLICENT | Pharmaceutical compositions |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2021 |
Drugs and Companies using PRASTERONE ingredient
NCE-1 date: 16 November, 2020
Market Authorisation Date: 16 November, 2016
Treatment: NA
Dosage: INSERT
More Information on Dosage
INTRAROSA family patents
86. Invega Sustenna patent expiration
INVEGA SUSTENNA's oppositions filed in EPO
INVEGA SUSTENNA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2011 |
| New Dosage Form(NDF) | Jul 31, 2012 |
| Pediatric Exclusivity(PED) | Jan 31, 2013 |
| M(M-119) | Aug 29, 2015 |
| New Indication(I-698) | Nov 12, 2017 |
| M(M-215) | Dec 20, 2020 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
NCE-1 date: 01 February, 2012
Market Authorisation Date: 31 July, 2009
Treatment: Dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)
Dosage: SUSPENSION, EXTENDED RELEASE
How can I launch a generic of INVEGA SUSTENNA before it's drug patent expiration?
More Information on Dosage
INVEGA SUSTENNA family patents
87. Invokana patent expiration
INVOKANA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617668 | JANSSEN PHARMS | Pharmaceutical formulations |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-733) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Indication(I-809) | Sep 27, 2022 |
Drugs and Companies using CANAGLIFLOZIN ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 29 March, 2013
Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day
Dosage: TABLET
How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage
INVOKANA family patents
88. Ionsys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8301238 | THE MEDICINES CO | Two-part electrotransport device |
Sep, 2031
(6 years from now) | |
| US9364656 | THE MEDICINES CO | Method of storing an electrotransport drug delivery device |
Sep, 2031
(6 years from now) | |
| US9731121 | THE MEDICINES CO | Switch validation circuit and method |
Oct, 2031
(6 years from now) | |
Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride
Dosage: SYSTEM
More Information on Dosage
IONSYS family patents
89. Isentress Hd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9649311 (Pediatric) | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 26, 2020 |
| New Patient Population(NPP) | Nov 22, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of ISENTRESS HD before it's drug patent expiration?
More Information on Dosage
ISENTRESS HD family patents
90. Isturisa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2025 |
| Orphan Drug Exclusivity(ODE-286) | Mar 06, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 06 March, 2024
Market Authorisation Date: 06 March, 2020
Treatment: Cushing's disease
Dosage: TABLET
More Information on Dosage
ISTURISA family patents
91. Iyuzeh patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637054 | THEA PHARMA | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives |
Jul, 2031
(6 years from now) | |
Drugs and Companies using LATANOPROST ingredient
Market Authorisation Date: 13 December, 2022
Treatment: Topical treatment of ocular hypertension and glaucoma
Dosage: SOLUTION/DROPS
More Information on Dosage
IYUZEH family patents
92. Jelmyto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9950069 | UROGEN PHARMA | Material and method for treating internal cavities |
Jan, 2031
(6 years from now) | |
| US9040074 | UROGEN PHARMA | Material and method for treating internal cavities |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 15, 2023 |
| Orphan Drug Exclusivity(ODE-289) | Apr 15, 2027 |
Drugs and Companies using MITOMYCIN ingredient
Market Authorisation Date: 15 April, 2020
Treatment: NA
Dosage: POWDER
More Information on Dosage
JELMYTO family patents
93. Jevtana Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8927592 (Pediatric) | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
| M(M-201) | May 17, 2020 |
| M(M-209) | Sep 14, 2020 |
| Pediatric Exclusivity(PED) | Nov 17, 2020 |
| M(M-128) | Dec 18, 2023 |
Drugs and Companies using CABAZITAXEL ingredient
NCE-1 date: 18 November, 2019
Market Authorisation Date: 17 June, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of JEVTANA KIT before it's drug patent expiration?
More Information on Dosage
JEVTANA KIT family patents
94. Juluca patent expiration
JULUCA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10426780 | VIIV HLTHCARE | Antiviral therapy |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage
JULUCA family patents
95. Keppra patent expiration
KEPPRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802142 | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Jun, 2031
(6 years from now) | |
|
US8802142 (Pediatric) | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2014 |
| Pediatric Exclusivity(PED) | Jun 16, 2015 |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 06 January, 2006
Treatment: NA
Dosage: TABLET
How can I launch a generic of KEPPRA before it's drug patent expiration?
More Information on Dosage
KEPPRA family patents
96. Kisqali patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(6 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-783) | Jul 18, 2021 |
| New Indication(I-784) | Jul 18, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-950) | Sep 17, 2027 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: In combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men, for the treatment of hr-positive, her2-negat...
Dosage: TABLET
How can I launch a generic of KISQALI before it's drug patent expiration?
More Information on Dosage
KISQALI family patents
97. Kisqali Femara Co-pack (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(6 years from now) | |
| US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-951) | Sep 17, 2027 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: As initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cance...
Dosage: TABLET
How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's drug patent expiration?
More Information on Dosage
KISQALI FEMARA CO-PACK (COPACKAGED) family patents
98. Kyleena patent expiration
KYLEENA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10987244 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| US9668912 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 16, 2019 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 16 September, 2016
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
KYLEENA family patents
99. Kynmobi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11419769 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(6 years from now) | |
| US8846074 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(6 years from now) | |
| US8414922 | SUMITOMO PHARMA AM | Sublingual films |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM
More Information on Dosage
KYNMOBI family patents
100. Latuda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9827242 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(6 years from now) | |
| US9259423 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(6 years from now) | |
|
US9259423 (Pediatric) | SUNOVION PHARMS INC | Method of treatment for mental disorders |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| New Indication(I-674) | Jun 28, 2016 |
| M(M-195) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Treatment: Treatment of bipolar depression with improvement in attention function in bipolar disorder; Treatment of schizophrenia or bipolar depression with improvement in attention function in schizophrenia and...
Dosage: TABLET
How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage
LATUDA family patents
101. Letairis patent expiration
LETAIRIS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549926 | GILEAD | Compositions and methods of treating pulmonary hypertension |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2012 |
| Orphan Drug Exclusivity(ODE) | Jun 15, 2014 |
| New Indication(I-716) | Oct 02, 2018 |
Drugs and Companies using AMBRISENTAN ingredient
NCE-1 date: 16 June, 2011
Market Authorisation Date: 15 June, 2007
Treatment: For the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3
Dosage: TABLET
How can I launch a generic of LETAIRIS before it's drug patent expiration?
More Information on Dosage
LETAIRIS family patents
102. Linzess patent expiration
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8933030 | ABBVIE | Treatments for gastrointestinal disorders |
Feb, 2031
(6 years from now) | |
| US10675325 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(6 years from now) | |
| US10702576 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(6 years from now) | |
| US8748573 | ABBVIE | Formulations comprising linaclotide |
Oct, 2031
(6 years from now) | |
| US8802628 | ABBVIE | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Treatment: Treatment of functional constipation in pediatric patients 6 to 17 years of age; Method of treating chronic idiopathic constipation in adult patients.
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents
103. Livmarli patent expiration
Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11260053 | MIRUM | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2026 |
| New Indication(I-938) | Mar 13, 2027 |
| Orphan Drug Exclusivity(ODE-379) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-429) | Mar 13, 2030 |
| ODE*(ODE*) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-471) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-490) | Jul 24, 2031 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 29 September, 2025
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)
Dosage: SOLUTION
More Information on Dosage
LIVMARLI family patents
104. Lumisight patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9155471 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Oct, 2031
(6 years from now) | |
| US9032965 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(6 years from now) | |
| US10285759 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(6 years from now) | |
| US9532835 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2029 |
Drugs and Companies using PEGULICIANINE ACETATE ingredient
NCE-1 date: 17 April, 2028
Market Authorisation Date: 17 April, 2024
Treatment: A method comprising administering pegulicianine to a human and obtaining an image of a tumor bed after tumor resection to distinguish in situ cancer cells from healthy cells
Dosage: POWDER
More Information on Dosage
LUMISIGHT family patents
105. Lupron Depot patent expiration
LUPRON DEPOT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-132) | Jun 17, 2014 |
| New Strength(NS) | Jun 17, 2014 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 22 December, 1995
Treatment: Palliative treatment of prostate cancer
Dosage: INJECTABLE
How can I launch a generic of LUPRON DEPOT before it's drug patent expiration?
More Information on Dosage
LUPRON DEPOT family patents
106. Lupron Depot-ped Kit patent expiration
LUPRON DEPOT-PED KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 15, 2014 |
| M(M-107) | Oct 08, 2014 |
| New Strength(NS) | Apr 14, 2026 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 16 April, 1993
Treatment: NA
Dosage: POWDER
More Information on Dosage
LUPRON DEPOT-PED KIT family patents
107. Lybalvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9119848 | ALKERMES INC | Morphinan derivatives for the treatment of drug overdose |
Aug, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11241425 | ALKERMES INC | Composition for treating mental illness |
Aug, 2031
(6 years from now) | |
| US9126977 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US9517235 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US10716785 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US10300054 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US11351166 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US11793805 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| US11185541 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating schizophrenia by administ...
Dosage: TABLET
More Information on Dosage
LYBALVI family patents
108. Lynparza patent expiration
LYNPARZA's oppositions filed in EPO
LYNPARZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859562 | ASTRAZENECA | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Product(NP) | Aug 17, 2020 |
| New Indication(I-762) | Jan 12, 2021 |
| New Indication(I-776) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| New Indication(I-818) | Dec 27, 2022 |
| New Indication(I-831) | May 08, 2023 |
| New Indication(I-832) | May 19, 2023 |
| Orphan Drug Exclusivity(ODE-180) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-181) | Aug 17, 2024 |
| New Indication(I-885) | Mar 11, 2025 |
| Orphan Drug Exclusivity(ODE-226) | Dec 19, 2025 |
| New Indication(I-914) | May 31, 2026 |
| Orphan Drug Exclusivity(ODE-283) | Dec 27, 2026 |
| Orphan Drug Exclusivity(ODE-306) | May 08, 2027 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemoth...
Dosage: CAPSULE; TABLET
How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage
LYNPARZA family patents
109. Makena (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446440 | COVIS | Needle assisted injection device having reduced trigger force |
Aug, 2031
(6 years from now) | |
Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient
Market Authorisation Date: 14 February, 2018
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of MAKENA (AUTOINJECTOR) before it's drug patent expiration?
More Information on Dosage
MAKENA (AUTOINJECTOR) family patents
110. Mavyret patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9586978 (Pediatric) | ABBVIE | Anti-viral compounds |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-230) | Aug 06, 2021 |
| New Patient Population(NPP) | Apr 30, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2022 |
| New Dosing Schedule(D-175) | Sep 26, 2022 |
| M(M-259) | Apr 10, 2023 |
| Orphan Drug Exclusivity(ODE-232) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-233) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-372) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: TABLET; PELLETS
More Information on Dosage
MAVYRET family patents
111. Mekinist patent expiration
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(6 years from now) | |
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-895) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Sep 16, 2026 |
| New Indication(I-908) | Mar 16, 2026 |
| New Product(NP) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: NA
Dosage: TABLET; SOLUTION
More Information on Dosage
MEKINIST family patents
112. Mektovi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2023 |
| Orphan Drug Exclusivity(ODE-194) | Jun 27, 2025 |
| New Indication(I-928) | Oct 11, 2026 |
Drugs and Companies using BINIMETINIB ingredient
NCE-1 date: 27 June, 2022
Market Authorisation Date: 27 June, 2018
Treatment: Mektovi is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with metastatic non small cell lung cancer with a braf v600e mutation, as detected by an fda-appr...
Dosage: TABLET
How can I launch a generic of MEKTOVI before it's drug patent expiration?
More Information on Dosage
MEKTOVI family patents
113. Minocin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9278105 | REMPEX | Tetracycline compositions |
May, 2031
(6 years from now) | |
| US9084802 | REMPEX | Tetracycline compositions |
May, 2031
(6 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 January, 1982
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE
How can I launch a generic of MINOCIN before it's drug patent expiration?
More Information on Dosage
MINOCIN family patents
114. Mirena patent expiration
MIRENA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9668912 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| US10987244 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-610) | Oct 01, 2012 |
| New Dosing Schedule(D-181) | Aug 20, 2023 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 06 December, 2000
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
MIRENA family patents
115. Mirvaso patent expiration
MIRVASO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8513249 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US9861631 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US8513247 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US9861632 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(6 years from now) | |
| US10201517 | GALDERMA LABS LP | Brimonidine gel compositions and methods of use |
Jun, 2031
(6 years from now) | |
| US8053427 | GALDERMA LABS LP | Brimonidine gel composition |
Jun, 2031
(6 years from now) | |
| US8163725 | GALDERMA LABS LP | Gel compositions and methods of use |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2016 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL
How can I launch a generic of MIRVASO before it's drug patent expiration?
More Information on Dosage
MIRVASO family patents
116. Mounjaro (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(6 years from now) | |
| US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
MOUNJARO (AUTOINJECTOR) family patents
117. Mulpleta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9427402 | VANCOCIN ITALIA | Preparation for improving solubility of poorly soluble drug |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 31 July, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
MULPLETA family patents
118. Multaq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8602215 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2014 |
Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient
NCE-1 date: 01 July, 2013
Market Authorisation Date: 01 July, 2009
Treatment: Management of risk of dronedarone/beta-blocker interaction in patients in sinus rhythm with a history of paroxysmal or persistent af
Dosage: TABLET
How can I launch a generic of MULTAQ before it's drug patent expiration?
More Information on Dosage
MULTAQ family patents
119. Mydcombi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10839960 | EYENOVIA | Ophthalmic drug delivery |
Jul, 2031
(6 years from now) | |
| US11839487 | EYENOVIA | Ophthalmic drug delivery |
Jul, 2031
(6 years from now) | |
| US11398306 | EYENOVIA | Ophthalmic drug delivery |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2026 |
Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE ingredient
Market Authorisation Date: 05 May, 2023
Treatment: Method of administering an effective dose of tropicamide and phenylephrine hydrochloride to an eye
Dosage: SPRAY, METERED
More Information on Dosage
MYDCOMBI family patents
120. Mytesi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9585868 | NAPO PHARMS INC | Methods and compositions for treating HIV-associated diarrhea |
Oct, 2031
(6 years from now) | |
| US8962680 | NAPO PHARMS INC | Methods and compositions for treating HIV-associated diarrhea |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 31, 2017 |
Drugs and Companies using CROFELEMER ingredient
NCE-1 date: 31 December, 2016
Market Authorisation Date: 31 December, 2012
Treatment: Symptomatic relief of non-infectious diarrhea
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
MYTESI family patents
121. Naloxone Hydrochloride (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9022022 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US10322239 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US9474869 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US8939943 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US9814838 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
Feb, 2031
(6 years from now) | |
| US10143792 | KALEO INC | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
May, 2031
(6 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: Use of a delivery device to administer a dose of naloxone; Use of a delivery device to deliver a dose of naloxone
Dosage: SOLUTION
More Information on Dosage
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents
122. Nerlynx patent expiration
NERLYNX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8669273 | PUMA BIOTECH | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 17, 2022 |
| New Indication(I-823) | Feb 25, 2023 |
| New Dosing Schedule(D-182) | Jun 28, 2024 |
Drugs and Companies using NERATINIB MALEATE ingredient
NCE-1 date: 17 July, 2021
Market Authorisation Date: 17 July, 2017
Treatment: Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the me...
Dosage: TABLET
How can I launch a generic of NERLYNX before it's drug patent expiration?
More Information on Dosage
NERLYNX family patents
123. Nexiclon Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623409 | ATHENA | Clonidine formulation |
Sep, 2031
(6 years from now) | |
Drugs and Companies using CLONIDINE ingredient
Market Authorisation Date: 03 December, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
NEXICLON XR family patents
124. Nithiodote patent expiration
NITHIODOTE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8496973 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Mar, 2031
(6 years from now) | |
| US8568793 | HOPE PHARMS | Sodium nitrite-containing pharmaceutical compositions |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
| Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
Drugs and Companies using SODIUM NITRITE; SODIUM THIOSULFATE ingredient
Market Authorisation Date: 14 January, 2011
Treatment: Treatment of acute cyanide poisoning that is judged to be life threatening
Dosage: SOLUTION, SOLUTION
More Information on Dosage
NITHIODOTE family patents
125. Noxafil patent expiration
NOXAFIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358297 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(6 years from now) | |
| US9023790 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Treatment: Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised
Dosage: SOLUTION
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
126. Nuzyra patent expiration
NUZYRA's oppositions filed in EPO
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9314475 | PARATEK PHARMS INC | Oral and injectable formulations of tetracycline compounds |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 02, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 02, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 03 October, 2027
Market Authorisation Date: 02 October, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
NUZYRA family patents
127. Ofirmev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399012 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 02, 2013 |
| M(M-196) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 02 November, 2010
Treatment: Modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics
Dosage: SOLUTION
How can I launch a generic of OFIRMEV before it's drug patent expiration?
More Information on Dosage
OFIRMEV family patents
128. Ohtuvayre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9062047 | VERONA PHARMA | Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 26, 2029 |
Drugs and Companies using ENSIFENTRINE ingredient
NCE-1 date: 26 June, 2028
Market Authorisation Date: 26 June, 2024
Treatment: For the maintenance treatment of chronic obstructive pulmonary disease (copd) in adult patients
Dosage: SUSPENSION
More Information on Dosage
OHTUVAYRE family patents
129. Ojemda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8293752 | DAY ONE BIOPHARMS | Compounds useful as Raf kinase inhibitors |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 23, 2029 |
| Orphan Drug Exclusivity(ODE-478) | Apr 23, 2031 |
Drugs and Companies using TOVORAFENIB ingredient
NCE-1 date: 23 April, 2028
Market Authorisation Date: 23 April, 2024
Treatment: NA
Dosage: TABLET; FOR SUSPENSION
More Information on Dosage
OJEMDA family patents
130. Olumiant patent expiration
OLUMIANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737469 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(6 years from now) | |
| US11806555 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 31, 2023 |
| New Indication(I-891) | May 10, 2025 |
| New Indication(I-890) | Jun 13, 2025 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: 31 May, 2022
Market Authorisation Date: 08 October, 2019
Treatment: Treatment of adult patients with severe alopecia areata
Dosage: TABLET
How can I launch a generic of OLUMIANT before it's drug patent expiration?
More Information on Dosage
OLUMIANT family patents
131. Opzelura patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10758543 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(6 years from now) | |
| US10869870 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(6 years from now) | |
| US11219624 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(6 years from now) | |
| US11571425 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(6 years from now) | |
| US11590136 | INCYTE CORP | Topical formulation for a JAK inhibitor |
May, 2031
(6 years from now) | |
|
US10758543 (Pediatric) | INCYTE CORP | Topical formulation for a JAK inhibitor |
Nov, 2031
(6 years from now) | |
|
US11219624 (Pediatric) | INCYTE CORP | Topical formulation for a JAK inhibitor |
Nov, 2031
(6 years from now) | |
|
US10869870 (Pediatric) | INCYTE CORP | Topical formulation for a JAK inhibitor |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 21, 2024 |
| New Indication(I-896) | Jul 18, 2025 |
| Pediatric Exclusivity(PED) | Jan 18, 2026 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 21 September, 2021
Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription th...
Dosage: CREAM
More Information on Dosage
OPZELURA family patents
132. Orenitram patent expiration
ORENITRAM's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8349892 | UNITED THERAP | Solid formulations of prostacyclin analogs |
Jan, 2031
(6 years from now) | |
| US8747897 | UNITED THERAP | Osmotic drug delivery system |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Dosing Schedule(D-156) | Jan 28, 2019 |
| New Dosing Schedule(D-157) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
| New Indication(I-820) | Oct 18, 2022 |
| Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: A method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ORENITRAM before it's drug patent expiration?
More Information on Dosage
ORENITRAM family patents
133. Otrexup patent expiration
OTREXUP's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8814834 | OTTER PHARMS | Injector safety device |
May, 2031
(6 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 07 November, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
OTREXUP family patents
134. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage
OZEMPIC family patents
135. Parsabiv patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8999932 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 07, 2022 |
Drugs and Companies using ETELCALCETIDE ingredient
NCE-1 date: 07 February, 2021
Market Authorisation Date: 07 February, 2017
Treatment: A method of treating secondary hyperparathyroidism (shpt)
Dosage: SOLUTION
How can I launch a generic of PARSABIV before it's drug patent expiration?
More Information on Dosage
PARSABIV family patents
136. Pifeltro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486975 | MSD MERCK CO | Non-nucleoside reverse transcriptase inhibitors |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-827) | Sep 19, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2023 |
| New Patient Population(NPP) | Jan 27, 2025 |
Drugs and Companies using DORAVIRINE ingredient
NCE-1 date: 30 August, 2022
Market Authorisation Date: 30 August, 2018
Treatment: For use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current a...
Dosage: TABLET
More Information on Dosage
PIFELTRO family patents
137. Pliaglis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10350180 | CRESCITA THERAP | Solid-forming local anesthetic formulations for pain control |
Jan, 2031
(6 years from now) | |
| US10751305 | CRESCITA THERAP | Solid-forming topical formulations for pain control |
Jan, 2031
(6 years from now) | |
| US10603293 | CRESCITA THERAP | Solid-forming local anesthetic formulations for pain control |
Jan, 2031
(6 years from now) | |
Drugs and Companies using LIDOCAINE; TETRACAINE ingredient
Market Authorisation Date: 29 June, 2006
Treatment: NA
Dosage: CREAM
More Information on Dosage
PLIAGLIS family patents
138. Pomalyst patent expiration
POMALYST's oppositions filed in EPO
Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8828427 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Jun, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8828427 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 08, 2018 |
| New Indication(I-707) | Apr 23, 2018 |
| Orphan Drug Exclusivity(ODE) | Feb 08, 2020 |
| Orphan Drug Exclusivity(ODE-43) | Feb 08, 2020 |
| M(M-14) | Nov 20, 2023 |
| Orphan Drug Exclusivity(ODE-296) | May 14, 2027 |
| Orphan Drug Exclusivity(ODE-297) | May 14, 2027 |
| Pediatric Exclusivity(PED) | Nov 14, 2027 |
Drugs and Companies using POMALIDOMIDE ingredient
NCE-1 date: 14 November, 2026
Market Authorisation Date: 08 February, 2013
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of POMALYST before it's drug patent expiration?
More Information on Dosage
POMALYST family patents
139. Pradaxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9034822 | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jan, 2031
(6 years from now) | |
|
US9034822 (Pediatric) | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2015 |
| New Indication(I-682) | Apr 04, 2017 |
| New Indication(I-683) | Apr 04, 2017 |
| M(M-168) | Nov 20, 2018 |
| New Strength(NS) | Nov 20, 2018 |
| New Indication(I-862) | Jun 21, 2024 |
| New Product(NP) | Jun 21, 2024 |
| Pediatric Exclusivity(PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
NCE-1 date: 22 December, 2023
Market Authorisation Date: 19 October, 2010
Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab
Dosage: CAPSULE
How can I launch a generic of PRADAXA before it's drug patent expiration?
More Information on Dosage
PRADAXA family patents
140. Proair Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9731087 | TEVA BRANDED PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | |
| US10124131 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US10022510 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US9216260 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(6 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED
More Information on Dosage
PROAIR DIGIHALER family patents
141. Proair Hfa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10022510 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US10086156 | TEVA BRANDED PHARM | Dose counter for inhaler and method for counting doses |
May, 2031
(6 years from now) | |
| US10695512 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US9463289 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US9808587 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US10022509 | TEVA BRANDED PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | |
| US11395889 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 16, 2011 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 29 October, 2004
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of PROAIR HFA before it's drug patent expiration?
More Information on Dosage
PROAIR HFA family patents
142. Proair Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10124131 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US10022510 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US9731087 | TEVA BRANDED PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | |
| US9216260 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED
More Information on Dosage
PROAIR RESPICLICK family patents
143. Pyrukynd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE49582 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(6 years from now) | |
| US8785450 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2027 |
| Orphan Drug Exclusivity(ODE-392) | Feb 17, 2029 |
Drugs and Companies using MITAPIVAT SULFATE ingredient
NCE-1 date: 17 February, 2026
Market Authorisation Date: 17 February, 2022
Treatment: NA
Dosage: TABLET
More Information on Dosage
PYRUKYND family patents
144. Qnasl patent expiration
QNASL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188811 | TEVA BRANDED PHARM | Nasal spray device |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 23, 2015 |
| New Strength(NS) | Dec 17, 2017 |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 17 December, 2014
Treatment: NA
Dosage: AEROSOL, METERED
More Information on Dosage
QNASL family patents
145. Quillichew Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8287903 | NEXTWAVE PHARMS | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 04, 2018 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 December, 2015
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE, CHEWABLE
How can I launch a generic of QUILLICHEW ER before it's drug patent expiration?
More Information on Dosage
QUILLICHEW ER family patents
146. Quillivant Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8465765 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US9040083 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8778390 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8563033 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8956649 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| US8287903 | NEXTWAVE | Orally effective methylphenidate extended release powder and aqueous suspension product |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 27, 2015 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2012
Treatment: Treating a patient having a condition susceptible to treatment with methylphenidate, such as adhd, by administering the formulation recited in claims 1 or 2; Treatment of a patient by administering th...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
How can I launch a generic of QUILLIVANT XR before it's drug patent expiration?
More Information on Dosage
QUILLIVANT XR family patents
147. Qulipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of migraine in adults
Dosage: TABLET
More Information on Dosage
QULIPTA family patents
148. Qvar 40 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10022510 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US11395889 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US10022509 | TEVA BRANDED PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | |
| US9463289 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US10695512 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US9808587 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US10086156 | TEVA BRANDED PHARM | Dose counter for inhaler and method for counting doses |
May, 2031
(6 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 15 September, 2000
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of QVAR 40 before it's drug patent expiration?
More Information on Dosage
QVAR 40 family patents
149. Qvar 80 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10086156 | TEVA BRANDED PHARM | Dose counter for inhaler and method for counting doses |
May, 2031
(6 years from now) | |
| US10022510 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US9808587 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US10022509 | TEVA BRANDED PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | |
| US10695512 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US11395889 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US9463289 | TEVA BRANDED PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 15 September, 2000
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of QVAR 80 before it's drug patent expiration?
More Information on Dosage
QVAR 80 family patents
150. Qvar Redihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11395889 | NORTON WATERFORD | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US10086156 | NORTON WATERFORD | Dose counter for inhaler and method for counting doses |
May, 2031
(6 years from now) | |
| US10022509 | NORTON WATERFORD | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | |
| US10022510 | NORTON WATERFORD | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | |
| US10695512 | NORTON WATERFORD | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | |
| US8931476 | NORTON WATERFORD | Inhaler |
Jul, 2031
(6 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: AEROSOL, METERED
More Information on Dosage
QVAR REDIHALER family patents
151. Relistor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9314461 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(6 years from now) | |
| US8956651 | SALIX | Oral formulations and lipophilic salts of methylnal trexone |
Mar, 2031
(6 years from now) | |
| US8524276 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(6 years from now) | |
| US10307417 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(6 years from now) | |
| US10376505 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
| New Product(NP) | Jul 19, 2019 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
Market Authorisation Date: 19 July, 2016
Treatment: NA
Dosage: TABLET
How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage
RELISTOR family patents
152. Restasis Multidose patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8292129 | ABBVIE | Dispensing device |
Feb, 2031
(6 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: NA
Dosage: EMULSION
How can I launch a generic of RESTASIS MULTIDOSE before it's drug patent expiration?
More Information on Dosage
RESTASIS MULTIDOSE family patents
153. Rhofade patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883838 | MAYNE PHARMA | Pharmaceutical cream compositions and methods of use |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 18, 2020 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: NA
Dosage: CREAM
How can I launch a generic of RHOFADE before it's drug patent expiration?
More Information on Dosage
RHOFADE family patents
154. Rinvoq patent expiration
RINVOQ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8962629 | ABBVIE | Tricyclic compounds |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Indication(I-880) | Dec 14, 2024 |
| New Indication(I-883) | Jan 14, 2025 |
| New Indication(I-886) | Mar 16, 2025 |
| New Indication(I-888) | Apr 29, 2025 |
| New Indication(I-919) | May 18, 2026 |
| New Indication(I-946) | Apr 26, 2027 |
| New Patient Population(NPP) | Apr 26, 2027 |
| Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more tnf blockers
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
RINVOQ family patents
155. Rinvoq Lq patent expiration
RINVOQ LQ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8962629 | ABBVIE | Tricyclic compounds |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Product(NP) | Apr 26, 2027 |
| Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 26 April, 2024
Treatment: Treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tnf blockers
Dosage: SOLUTION
More Information on Dosage
RINVOQ LQ family patents
156. Risvan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752094 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US10058504 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
| US11007139 | LABS FARMS ROVI SA | Risperidone or paliperidone implant formulation |
May, 2031
(6 years from now) | |
| US11759416 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US10881605 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
| US10195138 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
| US10182982 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US10085936 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US11752093 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US10335366 | LABS FARMS ROVI SA | Risperidone or paliperidone implant formulation |
May, 2031
(6 years from now) | |
| US10463607 | LABS FARMS ROVI SA | Antipsychotic Injectable Depot Composition |
May, 2031
(6 years from now) | |
| US11173110 | LABS FARMS ROVI SA | Risperidone or paliperidone implant formulation |
May, 2031
(6 years from now) | |
| US11241377 | LABS FARMS ROVI SA | Antipsychotic injectable depot composition |
May, 2031
(6 years from now) | |
| US11752092 | LABS FARMS ROVI SA | Methods for the preparation of injectable depot compositions |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 29, 2027 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 29 March, 2024
Treatment: Treatment of schizophrenia in adults by intramuscular administration of extended release injectable composition; Intramuscular administration of risperidone in extended release injectable suspension f...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
RISVAN family patents
157. Rubraca patent expiration
RUBRACA's oppositions filed in EPO
RUBRACA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9045487 | PHARMAAND | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(6 years from now) | |
| US8754072 | PHARMAAND | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10278974 | PHARMAAND | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(6 years from now) | |
| US9861638 | PHARMAAND | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(6 years from now) | |
| US8859562 | PHARMAAND | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-772) | Apr 06, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2021 |
| New Indication(I-830) | May 15, 2023 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2023 |
| Orphan Drug Exclusivity(ODE-126) | Dec 19, 2023 |
| Orphan Drug Exclusivity(ODE-168) | Apr 06, 2025 |
Drugs and Companies using RUCAPARIB CAMSYLATE ingredient
NCE-1 date: 19 December, 2020
Market Authorisation Date: 19 December, 2016
Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; A method for treating metastatic castration-r...
Dosage: TABLET
More Information on Dosage
RUBRACA family patents
158. Rybelsus patent expiration
RYBELSUS's oppositions filed in EPO
RYBELSUS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11382957 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(6 years from now) | |
| US10086047 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(6 years from now) | |
| US10960052 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid |
Dec, 2031
(6 years from now) | |
| US9278123 | NOVO | Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
More Information on Dosage
RYBELSUS family patents
159. Seglentis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846744 | KOWA PHARMS | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 15, 2024 |
Drugs and Companies using CELECOXIB; TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
SEGLENTIS family patents
160. Seysara patent expiration
Can you believe SEYSARA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8318706 | ALMIRALL | Substituted tetracycline compounds |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 01, 2023 |
Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient
NCE-1 date: 01 October, 2022
Market Authorisation Date: 01 October, 2018
Treatment: A method for treating a bacterial infection in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering an effective amount of sa...
Dosage: TABLET
More Information on Dosage
SEYSARA family patents
161. Sinuva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357640 | INTERSECT ENT INC | Expandable devices and methods for treating a nasal or sinus condition |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 08, 2020 |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 08 December, 2017
Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant
Dosage: IMPLANT
More Information on Dosage
SINUVA family patents
162. Skyla patent expiration
SKYLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9668912 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| US10987244 | BAYER HLTHCARE | Inserter |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 09, 2016 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 09 January, 2013
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
SKYLA family patents
163. Slynd patent expiration
SLYND's oppositions filed in EPO
Can you believe SLYND received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11291633 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11478487 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US10849857 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | |
| US11504334 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11123299 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11351122 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11951213 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US10987364 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US12090231 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11413249 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11291632 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US11439598 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(6 years from now) | |
| US10179140 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | |
| US10603281 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | |
| US9603860 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2022 |
Drugs and Companies using DROSPIRENONE ingredient
Market Authorisation Date: 23 May, 2019
Treatment: Prevention of pregnancy in females of reproductive age
Dosage: TABLET
How can I launch a generic of SLYND before it's drug patent expiration?
More Information on Dosage
SLYND family patents
164. Sodium Nitrite patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8568793 | HOPE PHARMS | Sodium nitrite-containing pharmaceutical compositions |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
| Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
Drugs and Companies using SODIUM NITRITE ingredient
Market Authorisation Date: 14 February, 2012
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SODIUM NITRITE family patents
165. Sodium Thiosulfate patent expiration
SODIUM THIOSULFATE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8496973 | HOPE PHARMS | Sodium thiosulfate-containing pharmaceutical compositions |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jan 14, 2018 |
| Orphan Drug Exclusivity(ODE-5) | Jan 14, 2018 |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 14 February, 2012
Treatment: Treatment of acute cyanide poisoning that is judged to be life threatening
Dosage: SOLUTION
How can I launch a generic of SODIUM THIOSULFATE before it's drug patent expiration?
More Information on Dosage
SODIUM THIOSULFATE family patents
166. Sohonos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12023312 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(6 years from now) | |
| US9314439 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(6 years from now) | |
| US10292954 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(6 years from now) | |
| US9789074 | IPSEN | Composition and method for muscle repair and regeneration |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2028 |
| Orphan Drug Exclusivity(ODE-439) | Aug 16, 2030 |
Drugs and Companies using PALOVAROTENE ingredient
NCE-1 date: 17 August, 2027
Market Authorisation Date: 16 August, 2023
Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia ossificans (myositis) progressiva; Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans pro...
Dosage: CAPSULE
More Information on Dosage
SOHONOS family patents
167. Solodyn patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192615 | BAUSCH | Method for the treatment of acne and certain dosage forms thereof |
Nov, 2031
(6 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 May, 2006
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of SOLODYN before it's drug patent expiration?
More Information on Dosage
SOLODYN family patents
168. Sovaldi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
| New Patient Population(NPP) | Apr 07, 2020 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE-258) | Aug 28, 2026 |
Drugs and Companies using SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: NA
Dosage: TABLET; PELLETS
How can I launch a generic of SOVALDI before it's drug patent expiration?
More Information on Dosage
SOVALDI family patents
169. Spiriva Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8733341 (Pediatric) | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 15, 2018 |
| New Patient Population(NPP) | Feb 15, 2020 |
| Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage
SPIRIVA RESPIMAT family patents
170. Stivarga patent expiration
STIVARGA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8637553 | BAYER HLTHCARE | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
Feb, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9458107 | BAYER HLTHCARE | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-667) | Feb 25, 2016 |
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2017 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2020 |
| Orphan Drug Exclusivity(ODE-44) | Feb 25, 2020 |
| New Indication(I-744) | Apr 27, 2020 |
| Orphan Drug Exclusivity(ODE-139) | Apr 27, 2024 |
Drugs and Companies using REGORAFENIB ingredient
NCE-1 date: 27 September, 2016
Market Authorisation Date: 27 September, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of STIVARGA before it's drug patent expiration?
More Information on Dosage
STIVARGA family patents
171. Sublocade patent expiration
SUBLOCADE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9272044 | INDIVIOR | Injectable flowable composition buprenorphine |
Jun, 2031
(6 years from now) | |
| US10592168 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(6 years from now) | |
| US9498432 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(6 years from now) | |
| US9782402 | INDIVIOR | Injectable composition comprising buprenorphine |
Jun, 2031
(6 years from now) | |
| US10198218 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(6 years from now) | |
| US9827241 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(6 years from now) | |
| US10558394 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(6 years from now) | |
| US8975270 | INDIVIOR | Injectable flowable composition comprising buprenorphine |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 30, 2020 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 November, 2017
Treatment: Treating opioid addiction by subcutaneous injection of buprenorphine; Treatment of moderate to severe opioid use disorder; In situ formation of solid buprenorphine composition; Treating opioid addicti...
Dosage: SOLUTION, EXTENDED RELEASE
More Information on Dosage
SUBLOCADE family patents
172. Sunosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440715 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
173. Symdeko (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11578062 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(6 years from now) | |
| US10081621 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2023 |
| Orphan Drug Exclusivity(ODE-173) | Feb 12, 2025 |
| Orphan Drug Exclusivity(ODE-247) | Jun 21, 2026 |
| Orphan Drug Exclusivity(ODE-335) | Dec 21, 2027 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: 12 February, 2022
Market Authorisation Date: 21 June, 2019
Treatment: Treatment of cf in a patient age 6 years and older who is homozygous for f508del or has at least one cftr gene mutation responsive to tez/iva based on in vitro data and/or clinical evidence using the ...
Dosage: TABLET
More Information on Dosage
SYMDEKO (COPACKAGED) family patents
174. Symproic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9108975 | BDSI | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: 23 March, 2021
Market Authorisation Date: 23 March, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
SYMPROIC family patents
175. Synjardy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10610489 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage
SYNJARDY family patents
176. Tabrecta patent expiration
TABRECTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8420645 | NOVARTIS PHARM | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2025 |
| Orphan Drug Exclusivity(ODE-291) | May 06, 2027 |
Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient
NCE-1 date: 06 May, 2024
Market Authorisation Date: 06 May, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
TABRECTA family patents
177. Tafinlar patent expiration
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8703781 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(6 years from now) | |
|
US8952018 (Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-894) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Sep 16, 2026 |
| New Indication(I-908) | Mar 16, 2026 |
| New Product(NP) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
Market Authorisation Date: 16 March, 2023
Treatment: NA
Dosage: TABLET, FOR SUSPENSION; CAPSULE
More Information on Dosage
TAFINLAR family patents
178. Talzenna patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8735392 | PFIZER | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
Oct, 2031
(6 years from now) | |
| US10189837 | PFIZER | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2023 |
| New Indication(I-920) | Jun 20, 2026 |
Drugs and Companies using TALAZOPARIB TOSYLATE ingredient
Market Authorisation Date: 07 March, 2024
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
TALZENNA family patents
179. Tavalisse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7449458 | RIGEL PHARMS | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2023 |
| Orphan Drug Exclusivity(ODE-174) | Apr 17, 2025 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 17 April, 2022
Market Authorisation Date: 17 April, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of TAVALISSE before it's drug patent expiration?
More Information on Dosage
TAVALISSE family patents
180. Tavneos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8445515 | CHEMOCENTRYX | C5aR antagonists |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 07, 2026 |
| Orphan Drug Exclusivity(ODE-377) | Oct 07, 2028 |
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 07 October, 2025
Market Authorisation Date: 07 October, 2021
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
TAVNEOS family patents
181. Tazverik patent expiration
TAZVERIK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9090562 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9334527 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(6 years from now) | |
| US9949999 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(6 years from now) | |
| US8895245 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(6 years from now) | |
| US8765732 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(6 years from now) | |
| US9855275 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(6 years from now) | |
| US10420775 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(6 years from now) | |
| US8691507 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(6 years from now) | |
| US9175331 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(6 years from now) | |
| US9333217 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(6 years from now) | |
| US10155002 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(6 years from now) | |
| US9549931 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma positive for an...
Dosage: TABLET
More Information on Dosage
TAZVERIK family patents
182. Technivie patent expiration
TECHNIVIE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
| US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(6 years from now) | |
|
US8420596 (Pediatric) | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-743) | Jul 24, 2018 |
| New Product(NP) | Jul 24, 2018 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of hcv infection using paritaprevir
Dosage: TABLET
More Information on Dosage
TECHNIVIE family patents
183. Teflaro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8247400 | ABBVIE | Cephem compounds useful for the treatment of bacterial infections |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2015 |
| New Patient Population(NPP) | Sep 13, 2022 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
NCE-1 date: 29 October, 2014
Market Authorisation Date: 29 October, 2010
Treatment: Method of treating bacterial infections
Dosage: POWDER
How can I launch a generic of TEFLARO before it's drug patent expiration?
More Information on Dosage
TEFLARO family patents
184. Tegsedi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9061044 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399774 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(6 years from now) | |
| US8697860 | AKCEA THERAPS | Diagnosis and treatment of disease |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2023 |
| Orphan Drug Exclusivity(ODE-212) | Oct 05, 2025 |
Drugs and Companies using INOTERSEN SODIUM ingredient
NCE-1 date: 05 October, 2022
Market Authorisation Date: 05 October, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis
Dosage: SOLUTION
More Information on Dosage
TEGSEDI family patents
185. Tembexa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9303051 | EMERGENT BIODEFENSE | Phosphonate ester derivatives and methods of synthesis thereof |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 04, 2024 |
| Orphan Drug Exclusivity(ODE-354) | Jun 04, 2028 |
Drugs and Companies using BRINCIDOFOVIR ingredient
Market Authorisation Date: 04 June, 2021
Treatment: Method of treating human smallpox disease
Dosage: SUSPENSION; TABLET
More Information on Dosage
TEMBEXA family patents
186. Thyquidity patent expiration
THYQUIDITY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9050307 | AZURITY | Method for the preparation of a levothyroxine solution |
Aug, 2031
(6 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 30 November, 2020
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of THYQUIDITY before it's drug patent expiration?
More Information on Dosage
THYQUIDITY family patents
187. Tosymra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9211282 | TONIX MEDS | Formulations comprising triptan compounds |
Jul, 2031
(6 years from now) | |
Drugs and Companies using SUMATRIPTAN ingredient
Market Authorisation Date: 25 January, 2019
Treatment: Acute treatment of migraine
Dosage: SPRAY
More Information on Dosage
TOSYMRA family patents
188. Toujeo Max Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9345750 | SANOFI US SERVICES | Long-acting formulations of insulin |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: Improvement in glycemic control in diabetes mellitus patients
Dosage: SOLUTION
More Information on Dosage
TOUJEO MAX SOLOSTAR family patents
189. Toujeo Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9345750 | SANOFI US SERVICES | Long-acting formulations of insulin |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: Improvement in glycemic control in diabetes mellitus patients
Dosage: SOLUTION
More Information on Dosage
TOUJEO SOLOSTAR family patents
190. Tpoxx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9339466 | SIGA TECHNOLOGIES | Polymorphic forms of ST-246 and methods of preparation |
Mar, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10576165 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(6 years from now) | |
| US9233097 | SIGA TECHNOLOGIES | ST-246 liquid formulations |
Aug, 2031
(6 years from now) | |
| US9907859 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(6 years from now) | |
| US7737168 | SIGA TECHNOLOGIES | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 13, 2023 |
| Orphan Drug Exclusivity(ODE-200) | Jul 13, 2025 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 13 July, 2022
Market Authorisation Date: 13 July, 2018
Treatment: Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg
Dosage: CAPSULE; SOLUTION
More Information on Dosage
TPOXX family patents
191. Tradjenta patent expiration
TRADJENTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8853156 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Mar, 2031
(6 years from now) | |
|
US8853156 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-118) | Aug 13, 2015 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin
Dosage: TABLET
How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage
TRADJENTA family patents
192. Treanda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8436190 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-580) | Oct 31, 2011 |
| New Chemical Entity Exclusivity(NCE) | Mar 20, 2013 |
| Pediatric Exclusivity(PED) | May 01, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 31, 2015 |
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
NCE-1 date: 02 May, 2015
Market Authorisation Date: 01 May, 2009
Treatment: NA
Dosage: POWDER
How can I launch a generic of TREANDA before it's drug patent expiration?
More Information on Dosage
TREANDA family patents
193. Trelegy Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| New Indication(I-775) | Apr 24, 2021 |
| New Indication(I-843) | Sep 09, 2023 |
| New Strength(NS) | Sep 09, 2023 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 September, 2017
Treatment: NA
Dosage: POWDER
More Information on Dosage
TRELEGY ELLIPTA family patents
194. Trikafta (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10081621 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(6 years from now) | |
| US11578062 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 08, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
| Orphan Drug Exclusivity(ODE-275) | Oct 21, 2026 |
| Orphan Drug Exclusivity(ODE-323) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-357) | Jun 08, 2028 |
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 26 April, 2023
Treatment: Treatment of cystic fibrosis in patients aged 2 to <6 years who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with a comp...
Dosage: GRANULES; TABLET
More Information on Dosage
TRIKAFTA (COPACKAGED) family patents
195. Trintellix patent expiration
TRINTELLIX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8722684 | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8722684 (Pediatric) | TAKEDA PHARMS USA | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2018 |
| M(M-227) | May 02, 2021 |
| M(M-234) | Oct 19, 2021 |
| M(M-267) | Nov 13, 2023 |
| M(M-187) | Jan 22, 2024 |
| M(M-232) | Aug 23, 2026 |
| Pediatric Exclusivity(PED) | Feb 23, 2027 |
Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient
NCE-1 date: 23 February, 2026
Market Authorisation Date: 30 September, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of TRINTELLIX before it's drug patent expiration?
More Information on Dosage
TRINTELLIX family patents
196. Trulance patent expiration
TRULANCE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(6 years from now) | |
| US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(6 years from now) | |
| US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-764) | Jan 24, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: Irritable bowel syndrome with constipation; Chronic idiopathic constipation
Dosage: TABLET
How can I launch a generic of TRULANCE before it's drug patent expiration?
More Information on Dosage
TRULANCE family patents
197. Tukysa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8648087 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
TUKYSA family patents
198. Tymlos patent expiration
TYMLOS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803770 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(6 years from now) | |
| USRE49444 | RADIUS | Method of treating osteoporosis comprising administration of PTHrP analog |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| M(M-270) | Sep 20, 2024 |
| New Indication(I-907) | Dec 19, 2025 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Treatment to increase bone density in men with osteoporosis at high risk for fracture
Dosage: SOLUTION
How can I launch a generic of TYMLOS before it's drug patent expiration?
More Information on Dosage
TYMLOS family patents
199. Ubrelvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833448 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in adults
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
200. Uceris patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192581 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(6 years from now) | |
| US10660858 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(6 years from now) | |
| US8895064 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(6 years from now) | |
| US10307375 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(6 years from now) | |
| US9132093 | SALIX | Controlled release and taste making oral pharmaceutical composition |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 14, 2016 |
| New Product(NP) | Oct 07, 2017 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 14 January, 2013
Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of UCERIS before it's drug patent expiration?
More Information on Dosage
UCERIS family patents
201. Uloric patent expiration
ULORIC's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8372872 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(6 years from now) | |
| US9107912 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2014 |
| M(M-205) | Aug 15, 2020 |
Drugs and Companies using FEBUXOSTAT ingredient
NCE-1 date: 13 February, 2013
Market Authorisation Date: 13 February, 2009
Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline
Dosage: TABLET
How can I launch a generic of ULORIC before it's drug patent expiration?
More Information on Dosage
ULORIC family patents
202. Upneeq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8357714 | RVL PHARMS | Compositions and methods for non-surgical treatment of ptosis |
Aug, 2031
(6 years from now) | |
| US10912765 | RVL PHARMS | Compositions and methods for non-surgical treatment of ptosis |
Aug, 2031
(6 years from now) | |
| US9867808 | RVL PHARMS | Compositions and methods for non-surgical treatment of Ptosis |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 08, 2023 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 July, 2020
Treatment: Method of treating blepharoptosis
Dosage: SOLUTION/DROPS
More Information on Dosage
UPNEEQ family patents
203. Vabomere patent expiration
VABOMERE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8680136 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9694025 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| US10183034 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(6 years from now) | |
| US11007206 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| US10561675 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(6 years from now) | |
| US10172874 | REMPEX | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: 29 August, 2026
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of patients 18 years of age and older with complicated urinary tract infections caused by susceptible microorganisms; Treatment of complicated urinary tract infection (cuti) including pyelon...
Dosage: POWDER
More Information on Dosage
VABOMERE family patents
204. Vanflyta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8357690 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...
Dosage: TABLET
More Information on Dosage
VANFLYTA family patents
205. Veklury patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10065958 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Sep, 2031
(6 years from now) | |
| US11492353 | GILEAD SCIENCES INC | Methods and compounds for treating Paramyxoviridae virus infections |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-183) | Jan 21, 2025 |
| New Patient Population(NPP) | Apr 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Oct 22, 2025 |
| M(M-301) | Jul 13, 2026 |
| Pediatric Exclusivity(PED) | Jan 13, 2027 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: 13 January, 2026
Market Authorisation Date: 22 October, 2020
Treatment: NA
Dosage: SOLUTION; POWDER
More Information on Dosage
VEKLURY family patents
206. Venclexta patent expiration
VENCLEXTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546399 | ABBVIE | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(6 years from now) | |
| US10730873 | ABBVIE | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
| New Indication(I-782) | Jun 08, 2021 |
| M(M-228) | Jun 08, 2021 |
| New Indication(I-789) | Nov 21, 2021 |
| New Indication(I-795) | May 15, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
| Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
| M(M-265) | Oct 16, 2023 |
| Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
| Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
| Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Treatment: NA
Dosage: TABLET
How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage
VENCLEXTA family patents
207. Veozah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8871761 | ASTELLAS | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 12, 2028 |
Drugs and Companies using FEZOLINETANT ingredient
NCE-1 date: 13 May, 2027
Market Authorisation Date: 12 May, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
VEOZAH family patents
208. Verquvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10736896 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(6 years from now) | |
| US8420656 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921377 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(6 years from now) | |
| US9993476 | MERCK SHARP DOHME | Substituted 5-flouro-1H-pyrazolopyridines and their use |
May, 2031
(6 years from now) | |
| US11439642 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2026 |
Drugs and Companies using VERICIGUAT ingredient
NCE-1 date: 19 January, 2025
Market Authorisation Date: 19 January, 2021
Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...
Dosage: TABLET
More Information on Dosage
VERQUVO family patents
209. Verzenio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7855211 | ELI LILLY AND CO | Protein kinase inhibitors |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-768) | Feb 26, 2021 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2022 |
| New Indication(I-877) | Oct 12, 2024 |
| New Patient Population(NPP) | Oct 12, 2024 |
Drugs and Companies using ABEMACICLIB ingredient
NCE-1 date: 28 September, 2021
Market Authorisation Date: 28 September, 2017
Treatment: In combination with fulvestrant for the treatment of adult patients with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progres...
Dosage: TABLET
More Information on Dosage
VERZENIO family patents
210. Vesicare Ls patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9918970 | ASTELLAS | Pharmaceutical composition comprising solifenacin |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 26, 2023 |
| Pediatric Exclusivity(PED) | Nov 26, 2023 |
| W(W) | Nov 26, 2023 |
Drugs and Companies using SOLIFENACIN SUCCINATE ingredient
Market Authorisation Date: 26 May, 2020
Treatment: NA
Dosage: SUSPENSION
How can I launch a generic of VESICARE LS before it's drug patent expiration?
More Information on Dosage
VESICARE LS family patents
211. Viekira Pak (copackaged) patent expiration
VIEKIRA PAK (COPACKAGED)'s oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
| US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-163) | Apr 22, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using paritaprevir
Dosage: TABLET
More Information on Dosage
VIEKIRA PAK (COPACKAGED) family patents
212. Viekira Xr patent expiration
VIEKIRA XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
| US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using paritaprevir
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VIEKIRA XR family patents
213. Viltepso patent expiration
VILTEPSO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10870676 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(6 years from now) | |
| US9079934 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2025 |
| Orphan Drug Exclusivity(ODE-280) | Aug 12, 2027 |
Drugs and Companies using VILTOLARSEN ingredient
NCE-1 date: 12 August, 2024
Market Authorisation Date: 12 August, 2020
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
Dosage: SOLUTION
More Information on Dosage
VILTEPSO family patents
214. Vimovo patent expiration
VIMOVO's oppositions filed in EPO
VIMOVO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9220698 | HORIZON | Method for delivering a pharmaceutical composition to patient in need thereof |
Mar, 2031
(6 years from now) | |
| US8945621 | HORIZON | Method for treating a patient at risk for developing an NSAID-associated ulcer |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 30, 2013 |
| New Patient Population(NPP) | Jul 06, 2020 |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient
Market Authorisation Date: 30 April, 2010
Treatment: Risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment; Risk-reduction of nsaid-associated gastric ulcers in patients also taking low dose aspirin
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of VIMOVO before it's drug patent expiration?
More Information on Dosage
VIMOVO family patents
215. Vivjoa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236962 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8754227 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: 27 April, 2031
Market Authorisation Date: 26 April, 2022
Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential
Dosage: CAPSULE
More Information on Dosage
VIVJOA family patents
216. Vosevi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(6 years from now) | |
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
VOSEVI family patents
217. Wegovy patent expiration
WEGOVY's oppositions filed in EPO
WEGOVY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Jun 04, 2024 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage
WEGOVY family patents
218. Xadago patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8283380 | MDD US | Methods for treatment of parkinson's disease |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2022 |
Drugs and Companies using SAFINAMIDE MESYLATE ingredient
NCE-1 date: 21 March, 2021
Market Authorisation Date: 21 March, 2017
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes
Dosage: TABLET
More Information on Dosage
XADAGO family patents
219. Xenleta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9120727 | NABRIVA | Process for the preparation of pleuromutilins |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
XENLETA family patents
220. Xermelo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8193204 | TERSERA | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use |
Feb, 2031
(6 years from now) | |
| US7709493 | TERSERA | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2022 |
| Orphan Drug Exclusivity(ODE) | Feb 28, 2024 |
| Orphan Drug Exclusivity(ODE-132) | Feb 28, 2024 |
Drugs and Companies using TELOTRISTAT ETIPRATE ingredient
NCE-1 date: 28 February, 2021
Market Authorisation Date: 28 February, 2017
Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy
Dosage: TABLET
More Information on Dosage
XERMELO family patents
221. Xhance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10252010 | OPTINOSE US INC | Nasal delivery devices |
Feb, 2031
(6 years from now) | |
| US12083270 | OPTINOSE US INC | Delivery device and method |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
| New Indication(I-940) | Mar 15, 2027 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED
More Information on Dosage
XHANCE family patents
222. Xigduo Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9616028 (Pediatric) | ASTRAZENECA AB | Bilayer tablet formulations |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 28 July, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of XIGDUO XR before it's drug patent expiration?
More Information on Dosage
XIGDUO XR family patents
223. Xofluza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8987441 | GENENTECH INC | Substituted polycyclic carbamoyl pyridone derivative prodrug |
Sep, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8927710 | GENENTECH INC | Substituted polycyclic carbamoylpyridone derivative |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-811) | Oct 16, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 24, 2023 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 24 October, 2022
Market Authorisation Date: 23 November, 2020
Treatment: NA
Dosage: FOR SUSPENSION; TABLET
How can I launch a generic of XOFLUZA before it's drug patent expiration?
More Information on Dosage
XOFLUZA family patents
224. Xtoro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8536167 | FONSECA BIOSCIENCES | Methods for treating ophthalmic, otic, or nasal infections |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 17, 2019 |
| Pediatric Exclusivity(PED) | Jun 17, 2020 |
Drugs and Companies using FINAFLOXACIN ingredient
NCE-1 date: 18 June, 2019
Market Authorisation Date: 17 December, 2014
Treatment: Treatment of acute otitis externa
Dosage: SUSPENSION/DROPS
More Information on Dosage
XTORO family patents
225. Xyosted (autoinjector) patent expiration
Can you believe XYOSTED (AUTOINJECTOR) received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10279131 | ANTARES PHARMA INC | Injection device with cammed RAM assembly |
Jul, 2031
(6 years from now) | |
| US11446440 | ANTARES PHARMA INC | Needle assisted injection device having reduced trigger force |
Aug, 2031
(6 years from now) | |
| US10905827 | ANTARES PHARMA INC | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | |
| US10357609 | ANTARES PHARMA INC | Needle assisted jet injection device having reduced trigger force |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2021 |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XYOSTED (AUTOINJECTOR) family patents
226. Yorvipath patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906847 | ASCENDIS PHARMA BONE | Prodrug comprising a drug linker conjugate |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2027 |
| Orphan Drug Exclusivity(ODE-492) | Aug 09, 2031 |
Drugs and Companies using PALOPEGTERIPARATIDE ingredient
Market Authorisation Date: 09 August, 2024
Treatment: Treatment of hypoparathyroidism in adults
Dosage: SOLUTION
More Information on Dosage
YORVIPATH family patents
227. Yupelri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8541451 | MYLAN IRELAND LTD | Crystalline freebase forms of a biphenyl compound |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 09, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: 09 November, 2022
Market Authorisation Date: 09 November, 2018
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of YUPELRI before it's drug patent expiration?
More Information on Dosage
YUPELRI family patents
228. Zavzpret patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8481546 | PFIZER | CGRP receptor antagonist |
Oct, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 09, 2028 |
Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2027
Market Authorisation Date: 09 March, 2023
Treatment: Administration of zavegepant for acute treatment of migraine with or without aura
Dosage: SPRAY, METERED
More Information on Dosage
ZAVZPRET family patents
229. Zejula patent expiration
ZEJULA's oppositions filed in EPO
ZEJULA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8071623 | GLAXOSMITHKLINE | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859562 | GLAXOSMITHKLINE | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2022 |
| New Indication(I-813) | Oct 23, 2022 |
| New Indication(I-814) | Oct 23, 2022 |
| New Indication(I-833) | Apr 29, 2023 |
| Orphan Drug Exclusivity(ODE) | Mar 27, 2024 |
| Orphan Drug Exclusivity(ODE-133) | Mar 27, 2024 |
| Orphan Drug Exclusivity(ODE-277) | Oct 23, 2026 |
| Orphan Drug Exclusivity(ODE-278) | Oct 23, 2026 |
| Orphan Drug Exclusivity(ODE-295) | Apr 29, 2027 |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 26 April, 2023
Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status
Dosage: TABLET; CAPSULE
More Information on Dosage
ZEJULA family patents
230. Zelsuvmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9526738 | LNHC | Topical gels and methods of using the same |
Sep, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Treatment: NA
Dosage: GEL
More Information on Dosage
ZELSUVMI family patents
231. Zemdri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383596 | CIPLA USA | Antibacterial aminoglycoside analogs |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 25, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: 26 June, 2027
Market Authorisation Date: 25 June, 2018
Treatment: Method of using plazomicin to treat bacterial infections
Dosage: SOLUTION
More Information on Dosage
ZEMDRI family patents
232. Zepatier patent expiration
Can you believe ZEPATIER received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8871759 | MSD SUB MERCK | Inhibitors of hepatitis C virus replication |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 28, 2021 |
| New Patient Population(NPP) | Dec 09, 2024 |
Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient
NCE-1 date: 29 January, 2020
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of patients infected with hepatitis c virus
Dosage: TABLET
More Information on Dosage
ZEPATIER family patents
233. Zepbound (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(6 years from now) | |
| US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| M(M-82) | Oct 18, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ZEPBOUND (AUTOINJECTOR) family patents
234. Zilretta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8828440 | PACIRA PHARMS INC | Corticosteroids for the treatment of joint pain |
Aug, 2031
(6 years from now) | |
| US9555048 | PACIRA PHARMS INC | Corticosteroids for the treatment of joint pain |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 06, 2020 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 06 October, 2017
Treatment: Method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ZILRETTA family patents
235. Ztlido patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278623 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(6 years from now) | |
| US11786455 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(6 years from now) | |
| US9925264 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(6 years from now) | |
| US10765640 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(6 years from now) | |
| US9931403 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(6 years from now) | |
| US11793766 | SCILEX PHARMS | Non-aqueous patch for the relief of pain |
May, 2031
(6 years from now) | |
| US9283174 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(6 years from now) | |
| US10765749 | SCILEX PHARMS | Non-aqueous patch |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 28, 2021 |
Drugs and Companies using LIDOCAINE ingredient
Market Authorisation Date: 28 February, 2018
Treatment: Method for relieving the pain associated with post-herpetic neuralgia
Dosage: PATCH
How can I launch a generic of ZTLIDO before it's drug patent expiration?
More Information on Dosage
ZTLIDO family patents
236. Zurampic patent expiration
ZURAMPIC's oppositions filed in EPO
Can you believe ZURAMPIC received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216179 | IRONWOOD PHARMS INC | Treatment of gout and hyperuricemia |
Aug, 2031
(6 years from now) | |
| US9956205 | IRONWOOD PHARMS INC | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2020 |
Drugs and Companies using LESINURAD ingredient
NCE-1 date: 23 December, 2019
Market Authorisation Date: 22 December, 2015
Treatment: Coadministering with allopurinol to reduce serum uric acid (sua) below 4 mg/dl; Below 6mg/dl in patients having uric acid deposits; And/or below 6mg/dl with sua intraday change more than 50% and/or ad...
Dosage: TABLET
More Information on Dosage
ZURAMPIC family patents
237. Zurnai (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10279131 | PURDUE PHARMA LP | Injection device with cammed RAM assembly |
Jul, 2031
(6 years from now) | |
| US9364610 | PURDUE PHARMA LP | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | |
| US10905827 | PURDUE PHARMA LP | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | |
| US9364611 | PURDUE PHARMA LP | Needle assisted jet injection device having reduced trigger force |
Aug, 2031
(6 years from now) | |
| US8496619 | PURDUE PHARMA LP | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | |
| US9446195 | PURDUE PHARMA LP | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | |
| US11446440 | PURDUE PHARMA LP | Needle assisted injection device having reduced trigger force |
Aug, 2031
(6 years from now) | |
| US10357609 | PURDUE PHARMA LP | Needle assisted jet injection device having reduced trigger force |
Aug, 2031
(6 years from now) | |
| US11185642 | PURDUE PHARMA LP | Injection device with cammed ram assembly |
Aug, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Drugs and Companies using NALMEFENE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 August, 2024
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ZURNAI (AUTOINJECTOR) family patents
238. Zypitamag patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8829186 | MEDICURE | Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof |
Jan, 2031
(6 years from now) | |
Drugs and Companies using PITAVASTATIN MAGNESIUM ingredient
Market Authorisation Date: 14 July, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
ZYPITAMAG family patents
List of large molecules
1. List of Actemra large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8512983 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Jan, 2031
(6 years from now) | |
| US10662237 | GENENTECH, INC. | Method to improve virus filtration capacity |
Aug, 2031
(6 years from now) | |
| US8580264 | GENENTECH, INC. | Subcutaneously administered anti-IL-6 receptor antibody |
Nov, 2031
(6 years from now) | |
| US11667720 | GENENTECH, INC. | Subcutaneously administered anti-IL-6 receptor antibody |
Nov, 2031
(6 years from now) | |
| US10231981 | GENENTECH, INC. | Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis |
Dec, 2031
(6 years from now) |
Ingredients: TOCILIZUMAB
2. List of Tysabri large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9096879 | BIOGEN INC. | Method of supplementing culture media to prevent undesirable amino acid substitutions |
Jan, 2031
(6 years from now) | |
| US10444234 | BIOGEN INC. | Assay for JC virus antibodies |
Jan, 2031
(6 years from now) | |
| US11287423 | BIOGEN INC. | Assay for JC virus antibodies |
Jan, 2031
(6 years from now) | |
| US8318416 | BIOGEN INC. | Nutrient monitoring and feedback control for increased bioproduct production |
Jan, 2031
(6 years from now) | |
| US10308706 | BIOGEN INC. | Methods of preventing and removing trisulfide bonds |
Feb, 2031
(6 years from now) | |
| US8809049 | BIOGEN INC. | Methods for producing mammalian cells |
May, 2031
(6 years from now) | |
| US9109015 | BIOGEN INC. | Method of isolating biomacromolecules using low pH and divalent cations |
Aug, 2031
(6 years from now) |
Ingredients: NATALIZUMAB
3. List of Humira large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8999337 | ABBVIE INC. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
Feb, 2031
(6 years from now) | |
| US9624295 | ABBVIE INC. | Uses and compositions for treatment of psoriatic arthritis |
Mar, 2031
(6 years from now) |
Ingredients: ADALIMUMAB
4. List of Avastin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10011856 | GENENTECH, INC. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
May, 2031
(6 years from now) | |
| US10704071 | GENENTECH, INC. | Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
Aug, 2031
(6 years from now) |
Ingredients: BEVACIZUMAB
5. List of Prolia And Xgeva large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9012178 | AMGEN INC. | Dipeptides to enhance yield and viability from cell cultures |
Aug, 2031
(6 years from now) |
Ingredients: DENOSUMAB